Fundz

Alphyn Biologics Closes $3.3 Million Series A Financing To Advance Breakthrough Atopic Dermatitis Treatment

PRIVATESep 15, 2022

Amount Raised

$3.3 Million

Round Type

Series A

AnnapolisBiotechnologyHealthcare

Description

Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today that it is has closed a Series A financing round of approximately $3.3 million. The over-subscribed round was led by Queen City Angels, with participation from the Angel Physicians Fund and Serial Stage Venture Partners.

Who else raised in Healthcare and Biotechnology around the same time

Companies in the same sectors as Alphyn Biologics that raised within 45 days of this round, from Fundz verified event records.

  • Voltron Therapeutics, Inc. raised $515K (Seed) on October 28, 2022.
  • WiscMed raised $2M on October 28, 2022.
  • Adagio Medical raised $9.5M on October 27, 2022.
  • Monteris Medical raised $73M (Debt Financing) on October 27, 2022.
  • AI Metrics raised $1.3M (Seed) on October 26, 2022.
  • Biofrontera raised $3.7M (Seed) on October 25, 2022.

Who to call at Alphyn Biologics, and when

A new round usually means Alphyn Biologics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Alphyn Biologics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Alphyn Biologics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Alphyn Biologics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Alphyn Biologics

Location

3724A THOMAS POINT ROAD

Annapolis, Maryland, United States

About

Alphyn Biologics is a clinical-stage dermatology company developing first-in-class multi-target therapeutics for severe and prevalent skin diseases based on its AB-101 platform. Its lead product candidate, AB-101a, is a topical treatment for atopic dermatitis (AD), the most common form of eczema, currently in a Phase 2a clinical trial. AB-101a has demonstrated a strong safety profile and is in development to uniquely target AD's bacterial and immune system components, making it ideal for treating infected and non-infected AD. Alphyn's AB-101 platform has multiple bioactive compounds and, therefore, multiple mechanisms of action to support a robust pipeline of dermatologic therapeutics with potential safety, efficacy, and regulatory marketing authorization advantages. Alphyn is based in Annapolis, Maryland, and Cincinnati, Ohio, and has a wholly owned subsidiary in Australia. We became operational in 2020 and have raised approximately $6.7 million.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Alphyn Biologics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsSteven P., President hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Alphyn Biologics's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Alphyn Biologics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.